Half-Year 2022 Financial and Clinical Trials Update

Avastin Global sales CHFbn CER growth -29% Regional sales CER growth US -38% 4.2 Europe -53% 3.5 2.8 Japan -13% 2.1 1.4 International -20% 0.7 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 1,142m • US: Biosimilar erosion slowing • EU: Biosimilar erosion slowing • Japan: Limited decline due to biosimilars with narrow labels International: Biosimilar erosion slowing CER-Constant Exchange Rates Roche 176

View entire presentation